Blood and biochemical indicators that need to be monitored while taking Selinexol (Silvio)

Selinexor (Selinexor) is a new type of selective nuclear export inhibitor, mainly used for the treatment of multiple myeloma and diffuse large B cell lymphoma and other diseases. While this drug exerts its anti-tumor effect, it may also have certain effects on the patient's hematopoietic system, liver and kidney function, and electrolyte balance. Therefore, strict laboratory monitoring is required during the treatment process. Reasonable monitoring of blood and biochemical indicators not only helps evaluate the efficacy, but also detects potential adverse reactions in a timely manner, thereby ensuring patient medication safety.

When it comes to hematology monitoring, the most important indicators include hemoglobin, white blood cell count, and platelet levels. One of the common adverse reactions of selinesol is bone marrow suppression, manifested as anemia, neutropenia, and thrombocytopenia. Therefore, baseline examinations are required before treatment and blood routine examinations are regularly reviewed during medication. If moderate or severe neutropenia of granulocytes or platelets is found, the dose needs to be adjusted according to the specific situation or supportive treatment, such as the use of whitening drugs or platelet transfusions, to avoid the risk of serious infection or bleeding.

In terms of biochemical monitoring, liver and kidney function are the indicators of focus. Selinisol may cause an increase in serum aminotransferase, abnormal bilirubin, and damage to renal function. Therefore, it is necessary to regularly detect indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and serum creatinine. Once obvious liver function abnormalities or renal function decline occur, the condition should be evaluated promptly, and medication should be adjusted or treatment suspended according to guidelines. In addition, monitoring lactate dehydrogenase (LDH) and uric acid levels can also help assess the degree of cell destruction and whether there is a risk of tumor lysis syndrome.

Electrolyte monitoring cannot be ignored either. Some patients may develop electrolyte disorders such as hyponatremia, hypokalemia, or hypocalcemia during treatment with selinesol. If these abnormalities are not detected and corrected in time, they may cause arrhythmia, disturbance of consciousness, or even be life-threatening. Therefore, it is recommended that blood sodium, blood potassium, blood calcium and blood magnesium levels be measured regularly during medication, and timely supplementation and adjustment should be made for patients who have already developed electrolyte abnormalities. In summary, hematological and biochemical indicators need to be dynamically monitored during selinesol treatment. Through individualized testing and adjustment, the efficacy can be maximized and the risk of adverse reactions can be reduced.

Reference materials:https://www.drugs.com/